دورية أكاديمية
أعرض في EDS

Impact of Drug Recalls on Patients in The Netherlands: A 5-Year Retrospective Data Analysis.

التفاصيل البيبلوغرافية
العنوان: Impact of Drug Recalls on Patients in The Netherlands: A 5-Year Retrospective Data Analysis.
المؤلفون: Annema PA; Department of Pharmacy and Clinical Pharmacology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands.; Amsterdam University Medical Center location Vrije Universiteit Amsterdam, Elderly Care Medicine, Amsterdam, The Netherlands.; Amsterdam Public Health, Aging & Later Life, Amsterdam, The Netherlands., Derijks HJ; Department of Pharmacy and Clinical Pharmacology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands., Bouvy ML; Division of Pharmacoepidemiology and Clinical Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands., van Marum RJ; Department of Pharmacy and Clinical Pharmacology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands.; Amsterdam University Medical Center location Vrije Universiteit Amsterdam, Elderly Care Medicine, Amsterdam, The Netherlands.; Amsterdam Public Health, Aging & Later Life, Amsterdam, The Netherlands.
المصدر: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2024 Jun; Vol. 115 (6), pp. 1365-1371. Date of Electronic Publication: 2024 Feb 23.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535 (Electronic) Linking ISSN: 00099236 NLM ISO Abbreviation: Clin Pharmacol Ther Subsets: MEDLINE
أسماء مطبوعة: Publication: 2015- : Hoboken, NJ : Wiley
Original Publication: St. Louis : C.V. Mosby
مواضيع طبية MeSH: Drug Recalls*, Humans ; Netherlands ; Retrospective Studies ; Drug Substitution/statistics & numerical data
مستخلص: Drug recalls occur frequently and have the potential to impact considerable numbers of patients and healthcare providers. However, in the absence of a comprehensive overview the extent of conducted recalls and their impact on patients remains unknown. To address this, we developed a comprehensive overview of drug recalls affecting patients. We compiled this overview based on the drug recall registrations from the Jeroen Bosch Hospital (JBZ), the University Medical Center Utrecht (UMCU), and the Royal Dutch Pharmacists Association (KNMP). A retrospective data analysis was conducted to identify drug recalls that affected patients. Specifically, we defined these as drug recalls that required patients to actively switch their drug to a different batch or brand of the same drug or to switch to a drug within the same or a different class of drugs. To quantify the impact, we used real-world drug dispensing data. Between January 1, 2017, and December 31, 2021, we identified 48 drug recalls that necessitated patients to make active changes to their medications an estimated 855,000 times. Most of the affected patients (292,000) were required to switch to a different brand of the same drug, whereas in 95,000 cases patients had to switch to a drug from another drug class. Our study suggests that a significant number of patients are affected by drug recalls. Future efforts are needed to elucidate patients' experiences and preferences regarding drug recalls, which could provide valuable insights to aid decision-making by relevant (national) authorities concerning drug recalls.
(© 2024 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.)
References: European Medicines Agency (EMA). EMA reviewing medicines containing valsartan from Zhejiang Huahai following detection of an impurity: some valsartan medicines being recalled across the EU <https://www.ema.europa.eu/en/news/ema‐reviewing‐medicines‐containing‐valsartan‐zhejiang‐huahai‐following‐detection‐impurity‐some> (2018). Accessed May 12, 2023.
European Medicines Agency (EMA). Valsartan from Mylan laboratories in India can no longer be used in EU medicines due to NDEA impurity <https://www.ema.europa.eu/en/news/valsartan‐mylan‐laboratories‐india‐can‐no‐longer‐be‐used‐eu‐medicines‐due‐ndea‐impurity> (2018). Accessed May 12, 2023.
UK Medicines & Healthcare products Regulatory Agency. MHRA recalls contaminated Irbesartan and Losartan batches as precautionary measure <https://www.gov.uk/government/news/mhra‐recalls‐contaminated‐irbesartan‐and‐losartan‐batches‐as‐precautionary‐measure> (2021). Accessed May 12, 2023.
Eworuke, E. et al. Valsartan, losartan and irbesartan use in the USA, UK, Canada and Denmark after the nitrosamine recalls: a descriptive cohort study. BMJ Open 13, e070985 (2023).
Hedenmalm, K., Quinten, C., Kurz, X., Bradley, M., Lee, H. & Eworuke, E. A collaborative study of the impact of N‐nitrosamines presence and ARB recall on ARB utilization – results from IQVIA disease analyzer Germany. Eur. J. Clin. Pharmacol. 79, 849–858 (2023).
European Medicines Agency (EMA). Human regulatory – Nitrosamine impurities <https://www.ema.europa.eu/en/human‐regulatory/post‐authorisation/referral‐procedures/nitrosamine‐impurities> Accessed 15 May 2023.
Food and Drug Administration (FDA). FDA alerts consumers of nationwide voluntary recall of EpiPen and EpiPen Jr <https://www.fda.gov/news‐events/press‐announcements/fda‐alerts‐consumers‐nationwide‐voluntary‐recall‐epipen‐and‐epipen‐jr> (2017). Accessed May 12, 2023.
Government of the United Kingdom. Batches of Ventolin Accuhaler and Seretide Accuhaler asthma inhalers recalled <https://www.gov.uk/government/news/batches‐of‐ventolin‐accuhaler‐and‐seretide‐accuhaler‐asthma‐inhalers‐recalled> (2018). Accessed May 12, 2023.
European Medicines Agency (EMA). Picato <https://www.ema.europa.eu/en/medicines/human/referrals/picato> (2020). Accessed May 12, 2023.
European Medicines Agency (EMA). Human Regulatory – Quality defects and recalls <https://www.ema.europa.eu/en/human‐regulatory/post‐authorisation/compliance/quality‐defects‐recalls> Accessed May 12, 2023.
European Medicines Agency (EMA). National competent authorities (human) <https://www.ema.europa.eu/en/partners‐networks/eu‐partners/eu‐member‐states/national‐competent‐authorities‐human> Accessed May 12, 2023.
European Medicines Agency (EMA). Compilation of Community Procedures on Inspections and Exchange of Information <https://www.ema.europa.eu/en/documents/regulatory‐procedural‐guideline/compilation‐union‐procedures‐inspections‐exchange‐information_en.pdf> (2022). Accessed May 12, 2023.
Świeczkowski, D., Zdanowski, S., Merks, P., Szarpak, Ł., Vaillancourt, R. & Jaguszewski, M.J. The plague of unexpected drug recalls and the pandemic of falsified medications in cardiovascular medicine as a threat to patient safety and global public health: a brief review. Cardiol. J. 29, 133–139 (2022).
Cheng, A., Tithecott, G.A., Edwards, W.E. & Johnston, I.G. The impact of the withdrawal of Adderall XR (long‐acting mixed amphetamine salts) from the Canadian market on paediatric patients and their families. Paediatr. Child Health 12, 373–378 (2007).
European Medicines Agency (EMA). How to use the defective product report to notify a quality defect to European Medicines Agency <https://www.ema.europa.eu/en/human‐regulatory/post‐authorisation/compliance/quality‐defects‐recalls/reporting‐quality‐defect‐ema> (2018). Accessed May 12, 2023.
Christensen, J. (CNN). Common heart drug recalled in 22 countries for possible cancer link <https://edition.cnn.com/2018/07/06/health/valsartan‐heart‐drug‐recall‐intl/index.html> (2018). Accessed May 12, 2023.
Reuters (The Guardian). Zantac in global recall over ‘unacceptable’ levels of potential carcinogen <https://www.theguardian.com/business/2019/oct/09/zantac‐in‐global‐recall‐over‐unacceptable‐levels‐of‐potential‐carcinogen> (2019). Accessed May 12, 2023.
تواريخ الأحداث: Date Created: 20240223 Date Completed: 20240513 Latest Revision: 20240513
رمز التحديث: 20240513
DOI: 10.1002/cpt.3220
PMID: 38390768
قاعدة البيانات: MEDLINE
الوصف
تدمد:1532-6535
DOI:10.1002/cpt.3220